Delcath Presents New Data on HEPZATO KIT™ Efficacy in Metastatic Uveal Melanoma at ESMO 2024

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company specializing in liver-targeted cancer therapies, announced new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic Delivery System) in patients with metastatic uveal melanoma (mUM). The data…

Read MoreDelcath Presents New Data on HEPZATO KIT™ Efficacy in Metastatic Uveal Melanoma at ESMO 2024

Cellworks Biosimulation Boosts IO Response Predictions in NSCLC Patients

Cellworks Group Inc., a leader in personalized therapy decision support and precision drug development, has announced promising results from a study using its computational biosimulation to predict immunotherapy (IO) responses in non-small cell lung cancer (NSCLC) patients. By combining biosimulation…

Read MoreCellworks Biosimulation Boosts IO Response Predictions in NSCLC Patients

CDR-Life Updates Pipeline Progress for M-gager® Solid Tumor Treatments

CDR-Life has announced key advancements in its M-gager® programs targeting solid tumors, highlighting notable progress in its mission to develop innovative antibody fragment-based immunotherapies for challenging cancers. First Patient Dosed with CDR404 CDR-Life has dosed its first patient with CDR404,…

Read MoreCDR-Life Updates Pipeline Progress for M-gager® Solid Tumor Treatments

Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection in the U.S.

Rising Pharmaceuticals, Inc. has announced the commercial launch of Edetate calcium disodium injection. Despite a current shortage of this product in the U.S., Rising’s version remains available. Rising Pharmaceuticals, Inc. has announced the availability of Edetate calcium disodium injection, which…

Read MoreRising Pharmaceuticals Launches Edetate Calcium Disodium Injection in the U.S.

Masimo and Google Team Up to Create Reference Platform for Advanced Wear OS Smartwatches

Masimo (NASDAQ: MASI), a leading innovator in medical technology, has announced a new partnership with Google to develop a reference platform for Wear OS by Google™ smartwatches. This collaboration will integrate Masimo’s advanced biosensing technologies, honed through decades of hospital…

Read MoreMasimo and Google Team Up to Create Reference Platform for Advanced Wear OS Smartwatches

SamanTree Medical’s Histolog® Scanner Receives FDA Clearance, Revolutionizing Tissue Imaging in the U.S.

SamanTree Medical, a pioneer in surgical imaging technology, has announced that its Histolog® Scanner has received FDA 510(k) clearance. This groundbreaking Swiss device offers real-time, high-resolution imaging of fresh tissue surfaces, enabling detailed visualization of internal microstructures such as cells,…

Read MoreSamanTree Medical’s Histolog® Scanner Receives FDA Clearance, Revolutionizing Tissue Imaging in the U.S.

Japan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain

CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The new vaccine is designed to protect against the JN.1 lineage of Omicron…

Read MoreJapan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain